Allergies News and Research

Latest Allergies News and Research

Circassia announces advancement in T-cell allergy vaccines development

Circassia Ltd, a specialty biopharmaceutical company focused on allergy, today announced that it has further advanced the clinical development of three of its leading T-cell allergy vaccines.

30 Sep 2010

Precautionary guidelines on flu vaccine safety for allergic children

With the flu season looming and health officials calling for across-the-board immunization, some parents may wonder just how safe the egg-based flu vaccine is for children with allergies. Pretty safe, say pediatricians from Johns Hopkins Children's Center: Even though the flu vaccine contains egg protein, most children with egg and other food allergies can be immunized safely with a few basic precautions.

30 Sep 2010

Swine flu no longer a threat to Americans: Report

According to the latest research most Americans are immune to the swine flu virus. Results of the study by the National Institute of Allergy and Infectious Diseases, published in the journal mBio show that around 59 percent of the 310 million U.S. population has developed immunity to H1N1 either from exposure to similar viruses, vaccination, or natural H1N1 infection.

29 Sep 2010

NIAID study utilizes Biojector B2000 system to explore syringe, needle benefits

Bioject Medical Technologies Inc., a leading developer of needle-free injection therapy systems, today announced that its unique Needle-Free Injection Therapy (NFIT) system, the Biojector 2000, is being utilized in a study sponsored by the National Institute of Allergy and Infectious Diseases (NIAID) which is part of the U.S. National Institutes of Health (NIH).

29 Sep 2010

NIH trial selects Inovio's PENNVAX-G DNA vaccine candidate to evaluate HIV-1 prevalent

Inovio Pharmaceuticals, Inc., a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that a Phase I study, called RV262, recently began to evaluate a combination DNA prime/MVA vector boost regimen that was developed to protect against diverse subtypes of HIV-1 prevalent in North America, Europe, Africa, and South America.

29 Sep 2010

Emergency treatment of anaphylaxis with epinephrine by trained non-medical professionals endorsed

The Epinephrine Roundtable was convened during the 25th Annual Meeting of the Wilderness Medical Society (WMS) in 2008 to explore areas of consensus and uncertainty in the field treatment of anaphylaxis. The panel endorsed the administration of epinephrine to treat anaphylaxis in the field under emergency conditions by trained non-medical professionals. Anaphylaxis, an acute allergic reaction, is sudden in onset and requires immediate treatment. The recommendations of the panel are published in the September issue of Wilderness & Environmental Health.

29 Sep 2010

People with pet allergies develop ragweed allergy symptoms: Research

Researchers found that people with pet allergies often develop ragweed allergy symptoms more quickly than others. But the study also suggests that once allergy season is in full swing, those symptom differences subside.

29 Sep 2010

Intrauterine devices for treatment of endometrial cancer

Intrauterine devices, originally developed as contraceptives, can also be used to treat and cure cancer of the endometrium according to new research published online in the cancer journal, Annals of Oncology today (Wednesday 29 September). The finding opens the way for young women with the disease, which affects the lining of the womb, to be treated without the need for a hysterectomy, thus preserving their fertility until they have had all the children they want.

29 Sep 2010

Early initiation of ART may prevent immune system damage in HIV patients: Study

HIV-infected individuals who begin antiretroviral therapy (ART) soon after acquiring the virus may have stronger immune responses to other pathogens than HIV-infected individuals who begin ART later, a new study from the National Institutes of Health has found. This finding suggests that early initiation of ART may prevent irreversible immune system damage and adds to the body of evidence showing significant health benefits from early ART.

29 Sep 2010

Tamir's compounds perform better than Ganciclovir for Cytomegalovirus disease: Study

Tamir Biotechnology, Inc. announced today that scientists supported by the National Institute of Allergy and Infectious Diseases (NIAID) reported test results confirming two of our lead compounds outperformed market leader Roche's drug Ganciclovir in cell culture and plaque reduction assay (the gold standard) for Cytomegalovirus (CMV) disease. Additionally, antiviral activity was also apparent against other human herpesviruses, namely, HSV-1 (cold sores), HSV-2 (genital herpes), and Varicella-Zoster Virus (VZV) (chicken-pox and shingles).

29 Sep 2010

RV262 Phase I study launched to evaluate DNA prime/MVA vector boost vaccine regimen for HIV

A Phase I study, called RV262, recently began to evaluate a combination DNA prime/MVA vector boost vaccine regimen that was developed to protect against diverse subtypes of HIV-1 prevalent in North America, Europe, Africa and South America.

29 Sep 2010

Children with food allergies experience bullying: Study

In the first ever study to assess the social impact of food allergies in children, Mount Sinai researchers have found that approximately 35 percent of children with food allergies, who are over the age of five, were reported to have experienced bullying, teasing, or harassment as a result of their allergies.

28 Sep 2010

Study: Genetic ancestry has no influence on how African-Americans with asthma respond to medication

Genetic ancestry has no discernible influence on how African American patients with asthma respond to medication, according to a Henry Ford Hospital study.

28 Sep 2010

IAVI investigators awarded grant to examine antibodies that neutralize HIV virus

A team of investigators headed by International AIDS Vaccine Initiative Investigator Pascal Poignard has been awarded a major grant from the National Institute of Allergy and Infectious Diseases of the US National Institutes of Health to investigate the biological mechanisms underlying the generation of broadly neutralizing antibodies by HIV positive individuals.

28 Sep 2010

NIH awards grants to treat HIV/AIDS in criminal justice system

Twelve scientific teams in more than a dozen states will receive National Institutes of Health (NIH) grants to study effective ways to prevent and treat HIV/AIDS among people in the criminal justice system.

24 Sep 2010

Asthma linked to seven genetic variants: Study

In a new study seven genes linked to asthma have been discovered. For the research genetic variations of 10,365 people with asthma and 16,110 people without the condition was studied. The variants identified showed an association with childhood asthma and some were also associated with later-onset asthma.

24 Sep 2010

Athersys presents MultiStem phase I study results at TCT Conference

Athersys, Inc. announced at its presentation at the Transvascular Cardiovascular Therapeutics (TCT) Conference held in Washington, D.C., updated results from its phase I clinical trial of MultiStem, its allogeneic cell therapy product, administered to individuals following acute myocardial infarction (AMI).

23 Sep 2010

Interleukin Genetics announces clinical study data on osteoarthritis progression

Interleukin Genetics, Inc. and the Thurston Arthritis Research Center at the University of North Carolina at Chapel Hill announced today findings from a large clinical study to evaluate the role of genetic factors in osteoarthritis progression which showed patients with radiographic evidence of knee osteoarthritis who inherited a specific pattern of genetic variations in the interleukin-1 receptor antagonist (IL-1Ra) gene were almost twice as likely to progress to severe disease as other patients.

23 Sep 2010

Vaxonco initiates Phase I clinical trial of novel DNA-based polyepitope vaccine against malaria

Vaxonco Inc., a Korean company specializing in peptide-based vaccines and Ichor Medical Systems (Ichor), whose advanced TriGrid™ Delivery System (TriGrid™) is being tested worldwide for its ability to enhance delivery of DNA drugs and vaccines, announced today the initiation of a Phase I clinical trial to evaluate a novel DNA-based polyepitope vaccine against malaria.

23 Sep 2010

Scientists identify genetic variants that increase asthma susceptibility

An international study looking at DNA from over 26,000 people has identified several genetic variants that substantially increase susceptibility to asthma in the population. The findings, published in the New England Journal of Medicine, will help scientists to focus their efforts to develop better therapies for the illness.

23 Sep 2010

Allergies News and Research

Latest Allergies News and Research

Circassia announces advancement in T-cell allergy vaccines development

Precautionary guidelines on flu vaccine safety for allergic children

Swine flu no longer a threat to Americans: Report

NIAID study utilizes Biojector B2000 system to explore syringe, needle benefits

NIH trial selects Inovio's PENNVAX-G DNA vaccine candidate to evaluate HIV-1 prevalent

Emergency treatment of anaphylaxis with epinephrine by trained non-medical professionals endorsed

People with pet allergies develop ragweed allergy symptoms: Research

Intrauterine devices for treatment of endometrial cancer

Early initiation of ART may prevent immune system damage in HIV patients: Study

Tamir's compounds perform better than Ganciclovir for Cytomegalovirus disease: Study

RV262 Phase I study launched to evaluate DNA prime/MVA vector boost vaccine regimen for HIV

Children with food allergies experience bullying: Study

Study: Genetic ancestry has no influence on how African-Americans with asthma respond to medication

IAVI investigators awarded grant to examine antibodies that neutralize HIV virus

NIH awards grants to treat HIV/AIDS in criminal justice system

Asthma linked to seven genetic variants: Study

Athersys presents MultiStem phase I study results at TCT Conference

Interleukin Genetics announces clinical study data on osteoarthritis progression

Vaxonco initiates Phase I clinical trial of novel DNA-based polyepitope vaccine against malaria

Scientists identify genetic variants that increase asthma susceptibility

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Allergies News and Research

Latest Allergies News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in